Latest News

In new era of gene therapy, PCPs are ‘boots on the ground’


 

The whole patient

Primary care physicians will not be expected to be experts in gene therapy or solely in charge of patient safety. They will have support from industry and subspecialists leading the development of these treatments, experts agreed.

But generalists should expect to be drawn into multidisciplinary care teams, be the sounding boards for patients making decisions about gene therapy, help arrange insurance coverage, and be the recipients of late-night phone calls about side effects.

All that, while never losing sight of the child’s holistic health. In children so sick, specialists, subspecialists, and even parents tend to focus only on the rare disease. The team can “get distracted from good normal routine care,” Dr. Nelson said. But these children aren’t exempt from check-ups, vaccine regimens, or the other diseases of childhood.

“In a world where we mitigate that core disease,” he said, “we need a partner in the general pediatrics community” investing in their long-term health.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Study shifts burden of IgG4-related disease to women
MDedge Family Medicine
Cutaneous vasculitis curtails quality of life
MDedge Family Medicine
FDA OKs new drug for Fabry disease
MDedge Family Medicine
FDA approves autoinjector pen for Humira biosimilar, Cyltezo
MDedge Family Medicine
FDA approves Yuflyma as ninth adalimumab biosimilar
MDedge Family Medicine
Scientists discover variants, therapy for disabling pansclerotic morphea
MDedge Family Medicine
Girls with congenital diaphragmatic hernia have lower survival rates
MDedge Family Medicine
FDA approves ritlecitinib for ages 12 and up for alopecia areata
MDedge Family Medicine
New guidelines for MTX use in pediatric inflammatory skin disease unveiled
MDedge Family Medicine
Camp Discovery: A place for children to be comfortable in their own skin
MDedge Family Medicine